EUVIMEDEUVIMED entdecken
Open Access

Novel tetravalent bispecific antibody, PSMA/TRAIL‑R2 REGULGENT™, induces selective tumor cell apoptosis without hepatotoxicity

Makoto Nakayama, Sayaka Takagi-Maeda, Yusuke Machino, Kaito Nihira, Miho Inoue, Nobuaki Takahashi, Katsuaki Usami

Oncology Reports · 2025

DOI: 10.3892/or.2025.8988 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Oncology Reports, 2025. Verfasst von Makoto Nakayama und 6 weiteren Autor:innen. Beteiligte Einrichtung: Core Research Laboratories, Bio‑Pharmaceutical Center, Research Division, Kyowa Kirin Co., Ltd., Tokyo 194‑8533, Japan. Hauptthemen laut MEDLINE: Antibodies, Bispecific, Receptors, TNF-Related Apoptosis-Inducing Ligand, Glutamate Carboxypeptidase II, Antigens, Surface. Die Arbeit nennt 51 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, BispecificReceptors, TNF-Related Apoptosis-Inducing LigandGlutamate Carboxypeptidase IIAntigens, SurfaceProstatic NeoplasmsHumansAnimalsApoptosisMiceMaleXenograft Model Antitumor AssaysCell Line, Tumor

Stichwörter der Autor:innen

apoptosisno hepatotoxicityprostate‑specific membrane antigentetravalent bispecific antibodytumor necrosis factor‑related apoptosis‑inducing ligand‑receptor 2

Substanzen

Antibodies, BispecificReceptors, TNF-Related Apoptosis-Inducing LigandGlutamate Carboxypeptidase IIFOLH1 protein, humanTNFRSF10B protein, humanAntigens, Surface

Autor:innen und Institutionen

  • Core Research Laboratories, Bio‑Pharmaceutical Center, Research Division, Kyowa Kirin Co., Ltd., Tokyo 194‑8533, Japan.
  • Project and Product Management Group 3, CMC Development, Manufacturing, Kyowa Kirin Co., Ltd., Tokyo 100‑0004, Japan.
  • Global Operational Transformation Kyowa Kirin International Plc., Marlow SL7 1HZ, UK.
  • Innovation Center, Research Division, Kyowa Kirin Co., Ltd., Tokyo 194‑8533, Japan.

Zitieren

APA

Nakayama, M., Takagi-Maeda, S., Machino, Y., Nihira, K., Inoue, M., Takahashi, N., & Usami, K. (2025). Novel tetravalent bispecific antibody, PSMA/TRAIL‑R2 REGULGENT™, induces selective tumor cell apoptosis without hepatotoxicity. Oncology Reports. https://doi.org/10.3892/or.2025.8988

Vancouver

Nakayama M, Takagi-Maeda S, Machino Y, Nihira K, Inoue M, Takahashi N, et al. Novel tetravalent bispecific antibody, PSMA/TRAIL‑R2 REGULGENT™, induces selective tumor cell apoptosis without hepatotoxicity. Oncology Reports. 2025. doi:10.3892/or.2025.8988

BibTeX
@article{Nakayama2025,
  author = {Nakayama, Makoto and Takagi-Maeda, Sayaka and Machino, Yusuke and Nihira, Kaito and Inoue, Miho and Takahashi, Nobuaki and Usami, Katsuaki},
  title = {Novel tetravalent bispecific antibody, PSMA/TRAIL‑R2 REGULGENT™, induces selective tumor cell apoptosis without hepatotoxicity},
  journal = {Oncology Reports},
  year = {2025},
  doi = {10.3892/or.2025.8988}
}
Kostenlos starten →